To observe the long-term survival benefit status of bevacizumab injection combined with chemotherapy in the treatment of advanced ovarian cancer.

The patients with advanced ovarian cancer were classified into control group and treatment group according to cohort method. The control group was treated with 175 mg·m^-2 of paclitaxel injection + area under curve (AUC) 5 intravenous infusion of carboplatin injection once every 3 weeks for 6 cycles, and on the basis of the control group, the treatment group was additionally given intravenous injection of 15 mg·kg^-1 of bevacizumab injection in the second cycle, once every 3 weeks, maintained monotherapy after 6 cycles until disease progression (up to 22 cycles of treatment). The solid tumor efficacy at 6 cycles of treatment and levels of serum tumor markers [carbohydrate antigen (CA) 125, CA199, human epididymis protein 4 (HE4)], vascular endothelial growth factor (VEGF), macrophage migration inhibitory factor (MIF), long term survival status (overall survival time, progression-free survival time) and safety evaluation before treatment and at 6 cycles of treatment were compared.

There were 51 cases in the control group and 31 cases in the treatment group. After 6 cycles of treatment, the total effective rates of the treatment group and the control group was 77.42% (24 cases/31 cases) and 52.94% (27 cases/51 cases), respectively, and the difference was statistically significant (P<0.05). After 6 cycles of treatment, serum CA125 levels in treatment group and control group were (63.71±8.53) and (73.09±9.55) U·mL^-1; the CA199 levels were (58.97±10.87) and (69.39±12.45) U·mL^-1; the HE4 levels were (117.96±22.73) and (155.60±30.92) pmol·L^-1; levels of VEGF were (285.50±60.42) and (377.82±73.31) ng·L^-1; the levels of MIF were (20.26±3.42) and (22.34±3.19) μg·L^-1, the progression-free survival time was 7 (0, 17) and 2 (0, 6) months; there were statistically significant differences in the above indexes between the treatment group and the control group(P<0.05, P<0.01, P<0.001). The overall survival time in treatment group and control group was 10 (6, 20) months and 8 (4, 11) months. The differences were statistically significant(P>0.05). The adverse drug reactions in treatment group were mainly nausea and vomiting, hypertension and bone marrow suppression while the adverse drug reactions in control group were mainly nausea and vomiting and bone marrow suppression, and the total incidences of adverse drug reactions were 45.16% (14 cases/31 cases) and 35.29% (18 cases/51 cases) respectively (P>0.05).

Bevacizumab injection combined with chemotherapy has good clinical efficacy in the treatment of advanced ovarian cancer, and significantly prolong the progression-free survival time of patients.